The Efficacy of Inflatable Mediastinoscopic-assisted Transhiatal Laparoscopic Esophagectomy

Prior treatment

• Patients who have undergone anti-tumor treatment (including chemotherapy, radiotherapy, surgery);
• Patients who have existing or concurrent significant bleeding disorders;

Other illness

• Other uncontrollable and inoperable conditions;
• Patients with two or more primary malignant tumors at the same time;
• Patients who, after thorough evaluation, have severe cardiac, pulmonary, hepatic, renal dysfunction, or other conditions that make surgery intolerable;

Lab values

• Patients with a history of diabetes for more than 10 years and whose blood glucose levels are not satisfactorily controlled.

Other

• Patients with severe calcification of the aorta;
• Patients with severe spinal deformities;
• Female patients during pregnancy or lactation;
• Patients who have undergone subtotal gastrectomy or total gastrectomy and cannot use the stomach to replace the esophagus;
• Patients with cervical spondylosis;
• Patients who lack informed consent due to psychological, family, social, or other factors;

• The patient has not undergone any prior anti-tumor treatment, including chemotherapy, radiotherapy, targeted therapy, immunotherapy, or other anti-tumor treatments;
• The patient has been histopathologically confirmed and diagnosed with esophageal squamous cell carcinoma, including obtaining pathological specimens through fiberoptic esophagoscopy biopsy, endoscopic mucosal dissection, endoscopic mucosal resection, and other methods, and confirmed by pathological examination as thoracic esophageal squamous cell carcinoma (including adequate diagnosis by immunohistochemical staining);
• The patient has undergone comprehensive preoperative evaluation (including plain and enhanced computed tomography (CT) scans of the neck, chest, and abdomen, plain and enhanced magnetic resonance imaging (MRI) scans of the chest, endoscopic ultrasonography, fiberoptic bronchoscopy, and neck ultrasound), and the clinical stage, according to the Tumor-node-metastasis Classification (TNM staging), is cT1b-3N0M0 or cTis-1aN0M0, and the patient is not suitable for endoscopic resection (TNM staging according to the American Joint Committee on Cancer 8th edition staging system);
• The patient is aged between 18 and 70 years;
• The patient's hematology (including routine blood cell count, routine liver and kidney function tests, blood lipids, blood glucose, electrolyte levels, tumor markers, etc.) and organ function (liver, kidney, heart, etc.) are normal;
• The patient can understand this study and has signed the informed consent form.
• The patient has good cardiopulmonary function (left ventricular ejection fraction between 50-80%; forced expiratory volume in one second (FEV1) \>80% of predicted value).